CompletedPhase 3NCT02581527

A Randomised Trial to Evaluate Toxicity and Efficacy of 1200mg and 1800mg Rifampicin for Pulmonary Tuberculosis

Studying Primary pulmonary tuberculosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
St George's, University of London
Principal Investigator
Amina Jindani, MD
Professor
Intervention
Rifampicin(drug)
Enrollment
672 enrolled
Eligibility
18-65 years · All sexes
Timeline
20172022

Study locations (6)

Collaborators

London School of Hygiene and Tropical Medicine · University of Botswana

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02581527 on ClinicalTrials.gov

Other trials for Primary pulmonary tuberculosis

Additional recruiting or active studies for the same condition.

See all trials for Primary pulmonary tuberculosis

← Back to all trials